Safety and efficacy of long-term therapy with high doses of atorvastatin
- Авторлар: Ezhov M.V1, Sorokin E.V1
-
Мекемелер:
- SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI NMRCC of RMH
- Шығарылым: № 15 (2017)
- Беттер: 55-60
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289975
- ID: 289975
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Cardiovascular diseases of atherosclerotic origin make a significant contribution to morbidity and mortality in Russian Federation. Hypercholesterolemia is the leading risk factor for the development of coronary artery disease (CAD). The case of early CAD due to heterozygous familial hypercholesterolemia and successful achievement of the target level of low-density lipoprotein cholesterol with the use of the maximum dose of atorvastatin and the subsequent stabilization of the course of CAD are analyzed. The original atorvastatin (Liprimar), due to the unique evidence base of randomized clinical trials conducted in patients with a very high cardiovascular risk, a reference drug with the possibility of prolonged and safe use at the maximum dosage.
Толық мәтін
Авторлар туралы
M. Ezhov
SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI NMRCC of RMH
Email: Marat_Ezhov@mail.ru
MD, Cardiologist, Leading Researcher at the Department of Atherosclerosis Problems Moscow
E. Sorokin
SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI NMRCC of RMHMoscow
Әдебиет тізімі
- Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 2013;34:3478-90.
- Ежов М.В., Сергиенко И.В., Рожкова Т.А. и др. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз идислипидемии. 2016;4:21-9.
- Watts G.F., Gidding S., Wiertzbicki A.S., Toth P.P., Alonso R., Brown W.V., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol. 2014;171:309-25.
- Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., et al. 2016 ESC/ EAS Guidelines for the management of dyslipidaemias. Eur. Heart J. 2016;37:2999-58.
- Рабочая группа Европейского общества кардиологов (ЕОК) и Европейского общества атеросклероза (ЕОА) по диагностике и лечению дислипидемий. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016. Рос. кардиол. журн. 2017; 5(145):7-77.
- Meek C.L., Reston J.D., Ramsbottom T., Pathmanathan H., Viljoen A. Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care. Int. J. Clin. Pract. 2011;2:120-26.
- Gibson C.M., Pride Y.B., Hochberg C.P., Sloan S., et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J. Am. Coll. Cardiol. 2009;54(24):2290-95.
- Ежов М.В. Актуальность применения высоких доз статинов до и после реваскуляризации миокарда. Мед. совет. 2016;13:66-9.
- Phan B.A., Moore A.B., Davis J., Pollan L.J., Neradilek B., Brown B.G., Zhao X.Q. Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J. Clin. Lipidol. 2014;8(5):489-93.
- Elis A., Zhou R., Stein E.A. Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiol. Young. 2014;24(3):437-41.
- Thakker D., Nair S., Pagada A., Jamdade V., Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmaco-epidemiol. DrugSaf. 2016;25(10):1131-49.
Қосымша файлдар
